Total
0
Shares
Orthocell (ASX:OCC) - Managing Director, Paul Anderson - The Market Herald
Managing Director, Paul Anderson
Source: The West Australian
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Orthocell (OCC) has received Food and Drug Administration (FDA) 501K approval to supply and market its medical collagen product CelGro in the U.S.
  • The approval means the CelGro — or as per its recent rebrand, Striate+ — is cleared for use on dental bone and tissue regeneration procedures in an auspicious U.S. dental market
  • OCC's Managing Director says the approval has come sooner than expected with the FDA lodgment taking place in May 2020
  • The company has hinted it could pave the way for OCC's entry into the peripheral nerve repair market
  • OCC shares have soared well into the green by 26.1 per cent on the back of the announcement, trading at 58 cents each

Orthocell (OCC) has received Food and Drug Administration (FDA) 501K approval to supply and market its medical collagen product CelGro in the U.S.

The approval means the CelGro — or as per its recent rebrand, Striate+ — is cleared for use on dental bone and tissue regeneration procedures in the U.S. market.

A company statement indicates the dental market in the States is valued at US$500 million per annum or roughly A$645 million.

More specifically, Striate+ has been cleared for use in dental bone defect repair, augmentation around dental implants in immediate and delayed extraction sockets and tissue regeneration procedures.

Orthocell submitted an FDA application for the product in May 2020.

Striate+ is manufactured in is manufactured at Orthocell's facilities in West Australia using the Company’s proprietary SMRTTM manufacturing technology.

The company says the FDA approval validates the SMRT manufacturing technology and could potentially pave the way for OCC's entry into the peripheral nerve repair market.

Orthocell Managing Director, Paul Anderson, says the approval came sooner than expected.

"I am excited by this strategic milestone and the positive step it represents on our pathway to partnering Striate+ in dental GBR indications," he commented.

Orthocell has also recently received approval to sale and market the product in Australia.

OCC shares have soared well into the green by 26.1 per cent on the back of the announcement, trading at 58 cents each at 10:45 am AEDT.

OCC by the numbers
More From The Market Herald
Palla Pharma (ASX:PAL) raises $12.2M to improve working capital

" Palla Pharma (ASX:PAL) raises $12.2M to improve working capital

Pharmaceutical company Palla Pharma (PAL) has raised roughly $12.24 million via a placement and institutional entitlement offer.
Neurotech (ASX:NTI) - Chairman, Brian Leedman - The Market Herald

" Neurotech (ASX:NTI) looks to bank $3.5M via placement and underwriting exercise

Neurotech (NTI) is set to pocket $3.5 million via an underwritten exercise options shortfall and an oversubscribed private placement.
Emerald Clinics (ASX:EMD) - Managing Director & CEO, Michael Winlo - The Market Herald

" Emyria (ASX:EMD) adds second clinic in Perth

Emyria (EMD) has added a second Emerald Clinic consulting suite in Perth due to strong growth.
Noxopharm (ASX:NOX) - Chief Executive Officer, Dr Graham Kelly - The Market Herald

" Noxopharm (ASX:NOX) banks $4.6M from government R&D rebate

Noxopharm (NOX) has pocketed $4.6 million from the Federal Government’s research and develop (R&D) tax rebate scheme.